WaveMan
WaveMan · Company
DBVT · Dbv Technologies S.A.
> Search tickers & screens ⌘K
LIVE
← All companies

DBVT DBV Technologies (DBVT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001613780
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
34
13F, latest reported quarter

What the filings say about DBVT

Insiders, 180 days
-$1.3K net sold
1 seller · 0% of sales under a 10b5-1 plan

DBV Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, DBV Technologies S.A. insiders sold a net $1.3K of stock across 23 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Mohideen Pharis
Chief Medical Officer
SELL
2026-07-31 SECtraded 2026-07-29
464
$1.3K
-28.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jan 29, 2026.
  • The trade is 0.3% of the 144,531 shares held after it.
  • No other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Mohideen Pharis sold about $1.3K of DBVT on Jul 29, 2026; 34 funds added in the latest 13F quarter.
Mohideen Pharis
Chief Medical Officer
SELL
2026-02-02 SECtraded 2026-01-29
534
$2.6K
-56.7%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Nov 21, 2025.
  • The trade is 0.4% of the 144,995 shares held after it.
  • No other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Mohideen Pharis sold about $2.6K of DBVT on Jan 29, 2026; 34 funds added in the latest 13F quarter.
EPIC Bpifrance
SELL
2025-12-19 SECtraded 2025-12-18
1,292,103
$5.4M
-51.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 17, 2025.
  • The trade is 17.7% of the 7,303,369 shares held after it.
  • 1 other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider EPIC Bpifrance sold about $5.4M of DBVT on Dec 18, 2025; 1 other insider sold within 30 days and 34 funds added in the latest 13F quarter.
EPIC Bpifrance
SELL
2025-12-19 SECtraded 2025-12-17
40,000
$211.2K
-51.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.5% of the 8,595,472 shares held after it.
  • 1 other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider EPIC Bpifrance sold about $211.2K of DBVT on Dec 17, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 34 funds added in the latest 13F quarter.
EPIC Bpifrance
SELL
2025-12-19 SECtraded 2025-12-17
2,036,990
$9.9M
-51.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 23.6% of the 8,635,472 shares held after it.
  • 1 other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider EPIC Bpifrance sold about $9.9M of DBVT on Dec 17, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 34 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.3K over 180 days
-$1.3K over 90 days
more than 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
34 funds bought in last quarter
below 60% of Pharma & Biotech
Revenue
+35.8% year over year
more than 72% of Pharma & Biotech
Margin
-2607.3% net margin
below 94% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.5% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
below 81% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch DBVT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-35.5%12M
-41%-7%+28%+62%2025-102025-122026-022026-042026-062026-082026-10 2025-12-17 · EPIC Bpifrance sold $9.9M2025-12-18 · EPIC Bpifrance sold $5.4M2025-12-17 · EPIC Bpifrance sold $211.2K2025-11-20 · Mohideen Pharis sold $18.7K2025-11-21 · Mohideen Pharis sold $4.5K2026-01-29 · Mohideen Pharis sold $2.6K2026-07-29 · Mohideen Pharis sold $1.3K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DBVT: institutional holders (13F)

13F holdings, latest reported quarter
MPM BIOIMPACT LLC
3,666,284 sh
$60.1M
Siren, L.L.C.
1,857,362 sh
$30.5M
Vivo Capital, LLC
1,844,758 sh
$30.3M
PERCEPTIVE ADVISORS LLC
1,653,350 sh
$27.1M
BAKER BROS. ADVISORS LP
1,461,425 sh
$24.0M

Congress trades in DBVT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DBVT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

DBVT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Dorsey Wright ADR ETF
$716.1K position · as of 2026-06-30
1.7%
Artisan International Small-Mid Fund
$13.8M position · as of 2026-06-30
0.5%
Fidelity Advisor Biotechnology Fund
$5.8M position · as of 2026-07-31
0.3%
U.S. Small Cap Equity Fund
$95.7K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$306.5K position · as of 2026-07-31
0.0%
Steward Values Enhanced International Fund
$54.7K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Daniel Tasse
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.4M
$7.7M
$1.4M
+25%
n/a
2024
$1.6M
-$506.1K
$639.6K
-80%
n/a
2023
$2.4M
$978.1K
$631.1K
-38%
n/a
2022
$2.8M
$2.9M
$789.2K
-4%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.3K sold by insiders over 180 days, 34 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DBVT financials

Revenue growth
+35.8%
XBRL, annual
Net margin
-2607.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$170.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
LongTermDebt as filed 2021-12-31 (54 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-331.92x
TTM operating cash flow over LongTermDebt as filed 2021-12-31 (54 months older than the period end) (includes the current portion)
Return on equity
-142.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-96.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-135.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.7B
market value at close 2026-10-23 on 2026-07-16 shares, plus LongTermDebt as filed 2021-12-31 (54 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-5.9%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$5.6M$4.2M$15.7M$4.8M
Operating income-$147.1M-$116.6M-$76.4M-$96.6M
Net income-$146.9M-$113.9M-$72.7M$96.3M
EPS (diluted)-1.05-1.17-0.76-1.24
Operating cash flow-$121.2M-$104.5M-$79.7M-$55.7M
Cash$194.2M$32.5M$141.4M$209.2M
SEC XBRL, fiscal years, as known on 2026-10-27

DBVT Stock Sonar score 6/7 axes

Find similar shapesCompare

DBVT ranks highest on growth (72nd percentile) and risk and compliance (54th), and lowest on profitability (22nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
22
Inputs
  • Return on equity-142.7% · 24 pct, sector of 545
  • Return on assets-96.0% · 25 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-135.3% · 18 pct, sector of 576
Financial health
43
Inputs
  • Debt to equity0.00x · 81 pct, sector of 352
  • Cash flow to debt-331.92x · 4 pct, sector of 371
Growth
72
Inputs
  • Revenue growth, YoY+35.8% · 72 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1K · 63 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
40
Inputs
  • Funds adding, latest quarter34 · 40 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+3.5% · 65 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.8% · 44 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DBVT filings, in plain words

Are DBV Technologies insiders buying or selling DBVT?

In the 180 days to 2026-10-27, DBV Technologies insiders were net sellers, a net $1.3K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-27, DBV Technologies insiders were net sellers of DBVT, a net $1.3K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies